Join today and have your say! It’s FREE!

We will not release or resell your information to third parties without your permission.

Please Try Again

{{ error }}

By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Please Try Again

{{ error }}

Password Hint : {{passwordHint}}

Remember me

Forgot Password?

or

Privacy Policy | Disclaimer

Quote | Bullboard | News | Opinion | Profile | Peers | Filings | Financials | Options | Price History | Ratios | Ownership | Insiders | Valuation

Breaking & Recent News Biosyent Inc BIOYF

Primary Symbol: V.RX

Healthcare

BioSyent Inc. is a specialty pharmaceutical company. The Company, through its wholly owned subsidiaries, BioSyent Pharma Inc., and BioSyent Pharma International Inc., acquires or licenses and develops pharmaceutical and other healthcare products for sale in Canada and certain international markets. Hedley Technologies Ltd., a wholly owned subsidiary operates the Company’s business marketing... see more

Add To Watchlist

Recent & Breaking News (TSXV:RX)

IIROC Trade Halt - BioSyent Inc.

Newsfile May 25, 2016

BioSyent Schedules Q1 2016 Earnings Release for May 27, 2016

MarketWire Canada May 25, 2016

BioSyent to Present at Upcoming Investor Conferences

Marketwired April 6, 2016

BioSyent Releases Q4 and Full Year 2015 Results

Marketwired March 4, 2016

BioSyent Schedules Fourth Quarter 2015 Earnings Release for March 4, 2016

Marketwired February 12, 2016

BioSyent to Present at the LD Micro Main Event 2015 Investor Conference

Marketwired November 30, 2015

BioSyent Pharma Announces the Canadian Launch of CYSVIEW(R) (Hexaminolevulinate Hydrochloride)

Marketwired November 17, 2015

BioSyent Releases Results for Third Quarter and First Nine Months of 2015

Marketwired November 11, 2015

BioSyent Named to the PROFIT 500 Ranking of Canada's Fastest-Growing Companies With a Five-Year Revenue Growth Rate of 1,086%

Marketwired September 17, 2015

BioSyent Pharma Acquires Exclusive Rights For Cysview(R) In Canada

Marketwired August 19, 2015

BioSyent Releases First Six Months 2015 Results-Six Month Sales Up 25%; Pharma Sales Up 25%; EBITDA Up 31%; Net Income Up 30%; Return on Equity 40%

Marketwired August 12, 2015

CORRECTION FROM SOURCE: BioSyent Releases First Quarter 2015 Results - Sales Up 35%; Pharma Sales Up 38%; Ebitda up 92%; Diluted EPS $0.07, Up 75%; Net Income Up 88%

Marketwired May 13, 2015

BioSyent (V.RX) boosts Q1 2015 net income 88%

Stockhouse Editorial May 13, 2015

BioSyent Releases First Quarter 2015 Results - Sales Up 35%; Pharma Sales Up 38%; Ebitda up 92%; Diluted EPS $0.07, Up 75%; Net Income Up 88%

Marketwired May 13, 2015

BioSyent to Present at the 2015 Bloom Burton & Co. Healthcare Investor Conference

Marketwired May 1, 2015

BioSyent Comments on Recent Market Activity

Marketwired April 10, 2015

BioSyent Releases Q4 and Full Year 2014 Results - Full Year Sales Up 57%; Pharma Sales Up 63%; Net Income Up 64%; Diluted EPS $0.22 Up 69%; Cash and Short-Term Investments $8.0 Million Up 82%

Marketwired February 25, 2015

BioSyent Pharma Announces the Canadian Launch of the First of 3 New Products Using the Patented Aguettant System(R)

Marketwired February 3, 2015

BioSyent Pharma Launches New Proktis-M(R) Suppositories

Marketwired November 24, 2014

BioSyent Releases Q3 and Nine Month Results-Q3 Sales Increase 56%, Net Income Up 64%; Nine Month Sales Up 62%, Net Income Up 75%

Marketwired October 20, 2014